MCRA Provides Anzu Special Acquisition Corp I with Strategic Diligence Support Leading to Envoy Medical Merger (NASDAQ: COCH)

January 22, 2024

https://www.prnewswire.com/news-releases/mcra-provides-anzu-special-acquisition-corp-i-with-strategic-diligence-support-leading-to-envoy-medical-merger-nasdaq-coch-302039694.html

WASHINGTON , Jan. 22, 2024 /PRNewswire/ — MCRA, LLC, a leading medical device and biologics focused clinical research organization (CRO) and advisory firm integrating seven core services [U.S. and International Regulatory Affairs, Clinical Trial Operations, Reimbursement and Market Access, Healthcare Compliance, Cybersecurity, Quality Assurance, and Japan Distribution Logistics (DMAH)] is pleased to announce its role in providing strategic due diligence support for Anzu Special Acquisition Corp I, ahead of the recent deal with Envoy Medical (“Envoy” or “Envoy Medical”) (NASDAQ: COCH).

Read more at prnewswire.com

Related news for (COCH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.